Tarceva Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System Metastases
Conditions:   Non-small Cell Lung Cancer;   EGFR Gene Mutation;   Brain Metastases Interventions:   Drug: AZD3759;   Drug: Erlotinib;   Drug: Gefitinib Sponsor:   Alpha Biopharma (Jiangsu) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 31, 2018 Category: Research Source Type: clinical trials